Another US Humira Biosimilar Approved As Formularies Offer Access
While Alvotech And Stada Broaden Reach Of Higher-Strength Adalimumab In Europe
Executive Summary
As Fresenius Kabi receives US FDA approval for its Idacio rival to Humira, positive developments are being seen in terms of adding adalimumab biosimilars to local formularies. Meanwhile, in Europe Stada and Alvotech have broadened access to their Hukyndra high-concentration version.
You may also be interested in...
Humira In 2023: The $17bn Biosimilar Opportunity
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
What’s Next? Five Things To Look Out For In January
The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.
Fresenius Delivers First US Biosimilar Approval
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.